References
- Babalonis S, Raup-Konsavage WM, Akpunonu PD, Balla A, Vrana KE. Δ8-THC: legal status, widespread availability, and safety concerns. Cannabis Cannabinoid Res. 2021;6(5):362–365. doi:10.1089/can.2021.0097
- Hollister LE, Gillespie HK. Delta‐8‐ and delta‐9‐tetrahydrocannabinol; Comparison in man by oral and intravenous administration. Clin Pharmacol Ther. 1973;14(3):353–357. doi:10.1002/cpt1973143353
- Leas EC. The hemp loophole: a need to clarify the legality of delta-8-THC and other hemp-derived tetrahydrocannabinol compounds. Am J Public Health. 2021;111(11):1927–1931. doi:10.2105/ajph.2021.306499
- Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci. 2019;10:697. doi:10.3389/fpls.2019.00697
- Johnson L. CBD oracle lab study shows some delta-8 products are 7700% over the legal delta-9 THC limit. ORACLE. Available from: https://cbdoracle.com/news/delta-8-thc-products-market-study-consumer-safety-and-legality/#The-labeling-lies. Accessed January 18, 2023.
- Gong H, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ. Acute and subacute bronchial effects of oral cannabinoids. Clin Pharmacol Ther. 1984;35(1):26–32. doi:10.1038/clpt.1984.4
- Abrahamov A, Mechoulam R, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 1995;56(23–24):2097–2102. doi:10.1016/0024-3205(95)00194-B
- Marcu J. The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report. Dialogues Clin Neurosci. 2020;22(3):289–293. doi:10.31887/dcns.2020.22.3/jmarcu
- Sheet D fact. What is K2? What is its origin? getsmartaboutdrugs. Available from: https://www.dea.gov/sites/default/files/2020-06/K2-spice-2020.pdf. Accessed January 18, 2023.
- Kiley B. “Synthetic Marijuana” has nothing to do with actual marijuana; 2015. Available from: https://www.thestranger.com/blogs/2015/09/16/22867088/synthetic-marijuana-has-nothing-to-do-with-actual-marijuana. Accessed January 18, 2023.
- Goldstein C. “Synthetic pot” it’s not. Bans bring unintended consequences; 2013. Available from: https://www.inquirer.com/philly/columnists/philly420/Synthetic_pot_its_not_Designer_drug_ban_brings_unintended_consequences_.html&outputType=app-web-view. Accessed January 18, 2023.
- Knopf A. CDC and FDA warn of delta‐8 THC harms. Alcohol Drug Abus Wkly. 2021;33(36):7. doi:10.1002/adaw.33199
- FDA. 5 things to know about delta-8 tetrahydrocannabinol – delta-8 THC. Available from: https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. Accessed January 18, 2023.
- Xu R, Wang Q. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection. BMC Bioinform. 2014;15(1):17. doi:10.1186/1471-2105-15-17
- Medical Dictionary for Regulatory Activities (MedDRA) version 24.1. Available from: https://www.meddra.org/index.asp. Accessed January 22, 2023.
- Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidem Dr S. 2001;10(5):407–410. doi:10.1002/pds.615
- FDA. Questions and answers on FDA’s Adverse Event Reporting System (FAERS). Available from: https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed January 18, 2023.
- Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363–1369. doi:10.1001/archinte.165.12.1363
- Moore TJ, Cohen MR, Furberg CD. serious adverse drug events reported to the food and drug administration, 1998–2005. Arch Intern Med. 2007;167(16):1752–1759. doi:10.1001/archinte.167.16.1752
- Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA drug safety surveillance program: adverse event reporting trends. Arch Intern Med. 2011;171(6):591–593. doi:10.1001/archinternmed.2011.89
- Zink RC, Huang Q, Zhang LY, Bao WJ. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance. Chin J Nat Med. 2013;11(3):314–320. doi:10.1016/s1875-5364(13)60035-7
- Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidem Dr S. 2004;13(8):519–523. doi:10.1002/pds.1001
- Green EJPH and S, Green JPH and S, Green S. Cochrane handbook for systematic reviews of interventions V5.1.0 2011; 2011. Available from: https://handbook-5-1.cochrane.org/chapter_16/16_9_2_studies_with_zero_cell_counts.htm. Accessed January 4, 2022.
- Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi:10.7150/ijms.6048
- Montastruc J, Sommet A, Bagheri H, Lapeyre‐Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Brit J Clin Pharmaco. 2011;72(6):905–908. doi:10.1111/j.1365-2125.2011.04037.x
- Simon TA, Gomez A, Marcu J. What Cannabis related data is Reported in the FDA FAERS Database. Cannabis Res Conf. 2021. doi:10.26226/morressier.60dc99f4e537565438d6c0b4
- Akpunonu P, Baum RA, Reckers A, et al. Sedation and acute encephalopathy in a pediatric patient following ingestion of delta-8-tetrahydrocannabinol gummies. Am J Case Reports. 2021;22:e933488. doi:10.12659/ajcr.933488
- Jo NY, Chu CC, Ramsey BC. Brugada electrocardiogram pattern induced by recreational delta-8-tetrahydrocannabinol (THC): a case report. Cureus. 2021;13(10):e19058. doi:10.7759/cureus.19058
- Knopf A. Keep your eye on…The risks of delta-8 THC in CBD and hemp. Brown Univ Child Adolesc Behav Lett. 2021;37(11):2. doi:10.1002/cbl.30583
- Delta 8 PSA, Michigan poison center. Wayne State University. Available from: https://static1.squarespace.com/static/5f777ef4c9213f4b5800fc9a/t/60832a49de02a46cdbd3a25d/1619208777303/Delta-8+THC+PSA+final.pdf. Accessed December 30, 2021.
- Yoshimura H, Watanabe K, Oguri K, Fujiwara M, Ueki S. Synthesis and pharmacological activity of a phosphate ester of delta8-tetrahydrocannabinol. J Med Chem. 1978;21(10):1079–1081. doi:10.1021/jm00208a014
- Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharm. 1973;25(3):363–372. doi:10.1016/0041-008x(73)90310-4
- Sagratella S, Pézzola A, Scotti de Carolis A. An EEG investigation on nabilone, a synthetic cannabinoid, in rabbits. Pharmacol Res Commun. 1986;18(7):653–662. doi:10.1016/0031-6989(86)90107-4
- Wada JA, Osawa T, Corcoran ME. Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese Baboons, Papio papio. Epilepsia. 1975;16(3):439–448. doi:10.1111/j.1528-1157.1975.tb06071.x
- Kruger DJ, Kruger JS. Consumer Experiences with Delta-8-THC: medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC. Cannabis Cannabinoid Res. 2021. doi:10.1089/can.2021.0124
- Richards JR, Smith NE, Moulin AK. Unintentional cannabis ingestion in children: a systematic review. J Pediatrics. 2017;190:142–152. doi:10.1016/j.jpeds.2017.07.005
- Herdeiro MT, Polónia J, Gestal-Otero JJ, Figueiras A. Improving the reporting of adverse drug reactions. Drug Safety. 2008;31(4):335–344. doi:10.2165/00002018-200831040-00007
- Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32:19–31. doi:10.2165/00002018-200932010-0000
- Figueiras A, Herdeiro MT, Polónia J, et al. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA. 2006;296:1086–1093. doi:10.1001/jama.296.9.1086
- Du D, Goldsmith J, Aikin KJ, Encinosa WE, Nardinelli C. Despite 2007 law requiring FDA hotline to be included in print drug ads, reporting of adverse events by consumers still low. Health Affair. 2017;31(5):1022–1029. doi:10.1377/hlthaff.2010.1004
- World Health Organization. WHO Expert Committee on Drug Dependence. 2003:25.
- Meehan-Atrash J, Rahman I. Novel Δ8-tetrahydrocannabinol vaporizers contain unlabeled adulterants, unintended byproducts of chemical synthesis, and heavy metals. Chem Res Toxicol. 2021. doi:10.1021/acs.chemrestox.1c00388